文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

局部阿托品用于儿童近视控制:阿托品治疗长期评估研究

Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

该研究对ATOM1和ATOM2随机临床试验的参与者进行长期观察,评估儿童期短期使用0.01%至1%阿托品对最终屈光状态和眼部并发症的影响。结果显示,治疗10至20年后,各组最终屈光误差无差异,1%阿托品组与安慰剂组在治疗或近视相关眼部并发症发生率上无差异。

要点

  • 儿童期短期使用0.01%至1%阿托品,10至20年后最终屈光误差无差异。
  • 1%阿托品组与安慰剂组在治疗或近视相关眼部并发症发生率上无差异。
  • 需进一步研究探讨儿童近视控制中阿托品的疗程和浓度。

核心结论

  • 儿童期短期使用0.01%至1%局部阿托品2至4年,与治疗结束后10至20年的最终屈光误差无差异。
  • 1%阿托品组与安慰剂组相比,治疗或近视相关眼部并发症的发生率未增加。
  • 这些发现可能影响未来临床试验的设计,需进一步研究儿童近视控制中阿托品的疗程和浓度。

研究设计与样本

  • 前瞻性、双盲观察性研究,纳入ATOM1和ATOM2随机临床试验的参与者。
  • ATOM1研究(1999年至2003年)比较1%阿托品与安慰剂,ATOM2研究(2006年至2012年)比较0.01%、0.1%和0.5%阿托品。
  • 研究在2个单中心进行,于2021年至2022年对成人参与者进行复查。
  • ATOM1原始队列400人中评估71人(占原始队列17.8%;研究时平均年龄30.5岁,SD 1.2;女性40.6%)。
  • ATOM2原始队列400人中评估158人(占原始队列39.5%;研究时平均年龄24.5岁,SD 1.5;女性42.9%)。

主要发现

  • ATOM1中,1%阿托品组平均SE为-5.20 D(SD 2.46),AL为25.87 mm(SD 1.23);安慰剂组平均SE为-6.00 D(SD 1.63),AL为25.90 mm(SD 1.21)。
  • ATOM1中,SE差异为0.80 D(95% CI,-0.25至1.85 D;P=0.13),AL差异为-0.03 mm(95% CI,-0.65至0.58 mm;P=0.92)。
  • ATOM2中,0.01%阿托品组平均SE为-6.40 D(SD 2.21),AL为26.25 mm(SD 1.34);0.1%组平均SE为-6.81 D(SD 1.92),AL为26.28 mm(SD 0.99);0.5%组平均SE为-7.19 D(SD 2.87),AL为26.31 mm(SD 1.31)。
  • 1%阿托品组与安慰剂组在20年白内障/晶状体混浊、近视性黄斑变性或视乳头旁萎缩(β/γ区)发生率上无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究仅评估了原始队列中约四分之一的参与者。
  • 需进一步研究以探讨儿童近视控制中阿托品的疗程和浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical trial results of topical atropine eye drops for childhood myopia control have shown inconsistent outcomes across short-term studies, with little long-term safety or other outcomes reported. OBJECTIVE: To report the long-term safety and outcomes of topical atropine for childhood myopia control. DESIGN, SETTING, AND PARTICIPANTS: This prospective, double-masked observational study of the Atropine for the Treatment of Myopia (ATOM) 1 and ATOM2 randomized clinical trials took place at 2 single centers and included adults reviewed in 2021 through 2022 from the ATOM1 study (atropine 1% vs placebo; 1999 through 2003) and the ATOM2 study (atropine 0.01% vs 0.1% vs 0.5%; 2006 through 2012). MAIN OUTCOME MEASURES: Change in cycloplegic spherical equivalent (SE) with axial length (AL); incidence of ocular complications. RESULTS: Among the original 400 participants in each original cohort, the study team evaluated 71 of 400 ATOM1 adult participants (17.8% of original cohort; study age, mean [SD] 30.5 [1.2] years; 40.6% female) and 158 of 400 ATOM2 adult participants (39.5% of original cohort; study age, mean [SD], 24.5 [1.5] years; 42.9% female) whose baseline characteristics (SE and AL) were representative of the original cohort. In this study, evaluating ATOM1 participants, the mean (SD) SE and AL were -5.20 (2.46) diopters (D), 25.87 (1.23) mm and -6.00 (1.63) D, 25.90 (1.21) mm in the 1% atropine-treated and placebo groups, respectively (difference of SE, 0.80 D; 95% CI, -0.25 to 1.85 D; P = .13; difference of AL, -0.03 mm; 95% CI, -0.65 to 0.58 mm; P = .92). In ATOM2 participants, the mean (SD) SE and AL was -6.40 (2.21) D; 26.25 (1.34) mm; -6.81 (1.92) D, 26.28 (0.99) mm; and -7.19 (2.87) D, 26.31 (1.31) mm in the 0.01%, 0.1%, and 0.5% atropine groups, respectively. There was no difference in the 20-year incidence of cataract/lens opacities, myopic macular degeneration, or parapapillary atrophy (β/γ zone) comparing the 1% atropine-treated group vs the placebo group. CONCLUSIONS AND RELEVANCE: Among approximately one-quarter of the original participants, use of short-term topical atropine eye drops ranging from 0.01% to 1.0% for a duration of 2 to 4 years during childhood was not associated with differences in final refractive errors 10 to 20 years after treatment. There was no increased incidence of treatment or myopia-related ocular complications in the 1% atropine-treated group vs the placebo group. These findings may affect the design of future clinical trials, as further studies are required to investigate the duration and concentration of atropine for childhood myopia control.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Li Y, Yip M, Ning Y, et al. Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study. JAMA Ophthalmol. 2024. PMID: 38019503. doi:10.1001/jamaophthalmol.2023.5467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。